Medical Research and Vaccines

Stanford Medicine researchers report in Science that a single-dose intranasal "universal" vaccine protected mice for at least three months against a range of respiratory threats, including SARS‑CoV‑2 and other coronaviruses, two common hospital‑acquired bacteria and dust‑mite allergen. Instead of targeting a specific pathogen, the formulation reprograms innate immune cells in the lungs to mount a broad early antiviral response, and every vaccinated mouse survived subsequent viral challenge with clear lungs, while unvaccinated controls suffered severe illness and death. Senior author Bali Pulendran, PhD, told Fox News Digital that, if it translates to humans, the spray could eventually replace multiple annual shots for COVID‑19, flu and other respiratory infections, but stressed this is still preclinical animal work and not a substitute for existing vaccines. Pulendran said more studies are needed to establish safety, dosing and efficacy in people, and estimated that—with sufficient funding—a human-ready product might be five to seven years away. The concept of a fall nasal spray that covers multiple viruses and even bacterial pneumonia is already drawing attention in public‑health circles as a potential next phase in U.S. respiratory‑vaccine strategy and pandemic preparedness.